| Year |
Citation |
Score |
| 2009 |
Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, Kensler TW. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. European Journal of Pharmacology. 620: 138-44. PMID 19698707 DOI: 10.1016/J.Ejphar.2009.08.022 |
0.691 |
|
| 2009 |
Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, Yamamoto M, Liby KT, Sporn MB, Kensler TW, Reddy SP. The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice. American Journal of Respiratory and Critical Care Medicine. 180: 867-74. PMID 19679692 DOI: 10.1164/Rccm.200905-0670Oc |
0.551 |
|
| 2009 |
Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis. 30: 1024-31. PMID 19386581 DOI: 10.1093/Carcin/Bgp100 |
0.632 |
|
| 2009 |
Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America. 106: 250-5. PMID 19104057 DOI: 10.1073/Pnas.0804333106 |
0.627 |
|
| 2008 |
Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, et al. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin Cancer Research. 68: 6727-6733. PMID 18701497 DOI: 10.1158/0008-5472.Can-08-1123 |
0.567 |
|
| 2008 |
Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicological Sciences : An Official Journal of the Society of Toxicology. 104: 218-27. PMID 18417483 DOI: 10.1093/Toxsci/Kfn079 |
0.727 |
|
| 2007 |
Yates MS, Kensler TW. Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacologica Sinica. 28: 1331-42. PMID 17723167 DOI: 10.1111/J.1745-7254.2007.00688.X |
0.545 |
|
| 2007 |
Yates MS, Kensler TW. Chemopreventive promise of targeting the Nrf2 pathway. Drug News & Perspectives. 20: 109-17. PMID 17440634 DOI: 10.1358/Dnp.2007.20.2.1083437 |
0.631 |
|
| 2007 |
Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Molecular Cancer Therapeutics. 6: 154-62. PMID 17237276 DOI: 10.1158/1535-7163.Mct-06-0516 |
0.636 |
|
| 2006 |
Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, Liby KT, Sporn MB, Yamamoto M, Kensler TW, Biswal S. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochemical and Biophysical Research Communications. 351: 883-9. PMID 17097057 DOI: 10.1016/J.Bbrc.2006.10.102 |
0.576 |
|
| 2006 |
Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Research. 66: 2488-94. PMID 16489057 DOI: 10.1158/0008-5472.Can-05-3823 |
0.618 |
|
| Show low-probability matches. |